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INTRODUCTION
BONE IS THE MOST commonly replaced tissue of thebody, with nearly 800,000 surgical procedures per-
formed per year in the United States alone.1 Autograft
has major disadvantages that are well documented and
include donor site morbidity, increased operative time,
blood loss, and often limited quantity,2–4 whereas allo-
graft can expose patients to viral contaminations and
complications, such as infections,5 fractures,6 or intense
immune response.7–9 For clinical bone transplantations,
tissue-engineering techniques based on the delivery of
cells to the defect through the use of three-dimensional
porous materials are being investigated.
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ABSTRACT
The aim of this investigation was to test the biocompatibility of three-dimensional bioresorbable
foams made of poly(L-lactic acid) (PLA), alone or filled with hydroxyapatite (HA) or -tricalcium
phosphate (-TCP), with human primary osteoblasts, using a direct contact method. Porous con-
structs were processed by supercritical gas foaming, after a melt-extrusion of ceramic/polymer mix-
ture. Three neat polymer foams, with pore sizes of 170, 310, and 600 m, and two composite foams,
PLA/5 wt% HA and PLA/5 wt% -TCP, were examined over a 4-week culture period. The tar-
geted application is the bone tissue-engineering field. For this purpose, human fetal and adult bone
cells were chosen because of their highly osteogenic potential. The association of fetal bone cells and
composite scaffold should lead to in vitro bone formation. The polymer and composite foams sup-
ported adhesion and intense proliferation of seeded cells, as revealed by scanning electron mi-
croscopy. Cell differentiation toward osteoblasts was demonstrated by alkaline phosphatase (ALP)
enzymatic activity, -carboxylated Gla-osteocalcin production, and the onset of mineralization. The
addition of HA or -TCP resulted in higher ALP enzymatic activity for fetal bone cells and a stronger
production of Gla-osteocalcin for adult bone cells.
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Scaffolds in bone tissue engineering are currently
made of either soft bioresorbable polymers such as
poly(-hydroxy acids), chitosan, or collagen,10,11 or of
brittle osteoconductive ceramics such as synthetic cal-
cium phosphates or natural coral.12,13 Ceramic–polymer
composites have gained increased interest.14–16 The com-
bination of ceramic and polymer should result in porous
composite structures that maintain their shape, with im-
proved mechanical properties, enhanced bioactivity, and
controlled resorption rates.17 To process scaffolds, sev-
eral techniques have been reported such as solvent 
casting/particulate leaching,18 emulsion freeze-drying 
or thermally induced phase separation,19,20 three-dimen-
sional printing,21 and gas foaming.22–24 It was previously
shown that supercritical gas foaming of poly(L-lactic
acid) (PLA) polymers can be used to obtain porous struc-
tures with controlled parameters particularly important
for bone tissue engineering, such as porosity, pore size,
and connectivity.25 Ceramic fillers were added to the
polymer matrix by melt-extrusion in order to obtain a ho-
mogeneous ceramic–polymer mixture before foaming.
Composite foams were thus processed by a solvent-free
technique, from raw materials to final porous structures.
The behavior of bone cells seeded directly on them re-
mained to be demonstrated. The use of primary human
bone cells to study the in vitro biocompatibility of or-
thopedic materials is an adequate model, undoubtedly
more relevant than experiments based on osteogenic cell
lines.26 The interesting potential of fetal bone cells for
tissue engineering was demonstrated on the basis of their
rapid growth rate and their responsiveness to differenti-
ation factors.27 In this study, fetal and adult bone cells
were each seeded on the same batches of scaffolds to
compare their interactions. We demonstrate here for the
first time that once seeded with human fetal bone cells,
PLA/ceramic composite osteoconductive scaffolds—
processed by supercritical gas foaming—give a promis-
ing approach in tissue engineering due to the high os-
teogenic potential of these cells.
MATERIALS AND METHODS
Materials
A commercial bioresorbable polymer, poly(L-lactic
acid) (PLA; Boehringer Ingelheim, Ingelheim, Germany),
was used without further purification. It was character-
ized by an intrinsic viscosity of 1.6 dL/g and a melting
temperature of 181.7°C. Two ceramic powders were
added to the polymer: hydroxyapatite (HA) and -trical-
cium phosphate (-TCP) (a gift from the Dr. Robert
Mathys Foundation, Bettlach, Switzerland). HA particles
were of nanometric size, with a high specific surface area
(50 m2/g), whereas -TCP particles were of micrometric
size, with a much smaller specific surface area (1–2 m2/g).
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Both PLA and ceramics were dried overnight at 105°C
under vacuum before processing in order to prevent poly-
mer degradation by hydrolysis. Foaming was carried out
with supercritical CO2 (pure, 99.995%; Sauerstoffwerk
Lenzburg, Lenzburg, Switzerland). PLA pellets and 5
wt% ceramic particles were mixed in the dry state before
extrusion. A microcompounder (Micro 5 compounder;
DSM, Heerlen, The Netherlands) with two conical coro-
tating screws, of small capacity (5 cm3), was used to pre-
pare ceramic–polymer blends, under a flow of nitrogen to
limit polymer degradation. A set temperature of 205°C, a
screw rotation speed of 100 rpm, and a residence time of
4 min were considered. These parameters were optimized
in order to obtain a homogeneous distribution of fillers in
PLA. The supercritical gas-foaming technique used in this
study has been described.25 The foaming equipment was
composed of a custom-made high-pressure chamber (Au-
toclave France, Rantigny, France) and a computerized
data acquisition system. PLA pellets or extruded com-
posite rods were placed into cylindrical open molds (in-
ner diameter, 35 mm) and loaded in the pressure vessel.
Pressure was increased up to saturation pressure Psat, and
temperature was increased up to 195°C, above the PLA
melting temperature. Polymer saturation by CO2 was
completed after 10 min. Foaming was then achieved by
sudden gas release, with simultaneous gas cooling and
consequently foam cooling also. Initial depressurization
rate dP/dt, controlled by a back-pressure regulator, and
maximum cooling rate dT/dt are significant parameters
that affect pore expansion and stabilization. Four pro-
cessing conditions were investigated to manufacture the
scaffolds tested in this study (Table 1).
For cell culture, scaffolds were machined into half-
cylinders (4 mm high, 8 mm in diameter). Samples were
sterilized in 24-well plates overnight in phosphate-
buffered saline (PBS), pH 7.4, containing penicillin and
streptomycin at concentrations of 1000 units/mL and
1000 g/mL, respectively (Invitrogen, Carlsbad, CA).
Scaffold characterization
Polymer and composite foams were cut with a razor
blade and coated with gold to avoid charge accumulation
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TABLE 1. FOAMING CONDITIONS INVESTIGATED TO
PROCESS TESTED SCAFFOLDS
Saturation Gas release
pressure Cooling rate rate
Condition Psat (bars) dT/dt (°C/s) dP/dt (bars)
C1 242 4.4 13.3
C2 100–150 5.1 12.1
C3 208 3.4 2.3
C4 225 4.7 4.5
and prevent sample damage. Specimens were observed by
scanning electron microscopy (SEM) (Philips XL30; FEI,
Acht, The Netherlands), under a high tension of 5 kV with
secondary electrons for simple topographic observation.
Average pore diameter d was evaluated by image analy-
sis. Foam samples were first embedded with EpoFix resin
(Struers, Balterup, Denmark) under vacuum. Polished sur-
faces were then observed with an optical microscope
(BH2; Olympus America, Melville, NY), to detect the
maximum number of pores. AnalySIS software (Soft
Imaging System, Münster, Germany) was used to estimate
pore diameter. Porosity * was evaluated by apparent den-
sity measurement, by weighing a sample of known vol-
ume. Compression behavior of foam was evaluated with
specimens of measured density. Samples were prepared,
paying special attention to obtaining parallel surfaces, per-
pendicular to the testing direction. Measurements were car-
ried out with compression equipment (UTS Testsysteme,
Ulm, Germany), with a cross-head speed of 0.5 mm/min.
Elastic modulus E* was evaluated from the initial linear
elastic part of the stress–strain curve. Results of architec-
tural and mechanical analyses are given in Table 2.
Cell sources
Human fetal and adult bone cells were obtained from
our bank of bone cells comprising 32 adult donors (18
females and 14 males) and 5 fetal donors (1 female and
4 males) at the end of January 2005. More than 250 pri-
mary total hip replacements with potentially interesting
orthopedic tissue samples are performed each year at the
Hôpital Orthopédique de la Suisse Romande (Lausanne,
Switzerland). Documents relative to the patients were
consulted to confirm the absence of major disease, med-
ications, and alcohol consumption. Bone samples were
extensively collected and care was taken to obtain healthy
bone samples. In particular, the selected adult bone cells
were from donors without bone necrosis. In this study,
human trabecular bone biopsies at femoral locations ob-
tained from a 60-year-old adult woman subsequent to or-
thopedic surgery, and from a fetus (gestational age, 16
weeks) after voluntary interruption of pregnancy, were
used. Biopsies were obtained in accordance with the
Ethics Committee of University Hospital at Lausanne
MONTJOVENT ET AL.
(Ethical Protocol 51/01). Primary osteoblast cultures
were established by rinsing the tissue first with PBS 
(containing penicillin and streptomycin). Afterward,
bone samples were mechanically dissociated with a
scalpel blade and transferred to 10-cm culture-grade
plates, where cell outgrowth was seen within 2 to 5 days
under normal culture conditions: Dulbecco’s modified
Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA),
10% fetal calf serum (FCS; Sigma-Aldrich, St. Louis,
MO), and 4 mM L-glutamine (Invitrogen).
Cell culture
Fetal and adult bone cells were maintained in culture by
passaging once per week and culturing at 37°C in a hu-
midified, 5% CO2 atmosphere in DMEM, 10% FCS, 4 mM
L-glutamine. Culture medium was changed twice per week.
Cells were used in the third passage for all experiments.
Biocompatibility test preparation
Scaffolds were placed in new 24-well plates and
washed with complete culture medium. Cells (120,000),
prepared as described above, were then seeded on sam-
ples by direct pipetting. After 1 h, culture medium was
added around the scaffolds and renewed every second
day. At these time points, osteogenic factors 1,25-di-
hydroxyvitamin D3 (1,25-(OH)2D3, 10 nM; Alexis Bio-
chemicals/MP Biomedicals, Carlsbad, CA), 10 nM dex-
amethasone (Sigma-Aldrich), in addition to L-ascorbic
acid (50 g/mL; Sigma-Aldrich) and 1 mM -glyc-
erophosphate (Sigma-Aldrich), were added to the growth
medium, to promote cell differentiation. Cell growth was
observed in the presence of the scaffolds during the 4-
week exposure time. Blanks consisted of scaffolds placed
in the culture medium but without cells. As controls,
polystyrene (PS) wells, which were not used for polymer
samples, were seeded. The experiment was performed
twice, in triplicate for each scaffold.
Antibodies and immunofluorescence microscopy
Fetal and adult cells seeded directly on PLA/HA IV
and PLA/-TCP IV composites were allowed to grow for
72 h. Cells were then observed in close proximity to the
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TABLE 2. PROPERTIES OF SCAFFOLDS TESTED IN BIOCOMPATIBILITY STUDY
Porosity Pore diameter Modulus
Sample Condition Material * (%) d (m) E* (MPa)
PLA I C1 PLA 91.9  2.1 170 and 1030 5.2  4.8
PLA II C2 PLA 83.1  0.8 600  90 52.2  4.5
PLA III C3 PLA 77.4  0.6 310  100 82.9  18.6
PLA/HA IV C4 PLA5%HA 79.2  0.9 400  250 133.2  15.2
PLA/-TCP IV C4 PLA5%-TCP 83.4  2.5 390  180 121.0  12.1
different materials. Immunostaining was performed as
described previously.28 Briefly, cells were permeabilized
for 5 min with 0.2% Triton X-100 (TX-100) in 3% para-
formaldehyde (PFA) and fixed with 3% PFA–PBS for 10
min. We used primary antibody against alkaline phos-
phatase (R&D Systems, Minneapolis, MN) and as sec-
ondary antibody Alexa 488-conjugated goat anti-mouse
antibody (Molecular Probes, Eugene, OR); F-actin was
probed with phalloidin–Alexa 568 (Molecular Probes)
and DNA with 4,6-diamidino-2-phenylindole (DAPI;
Fluka, Buchs, Switzerland). Images were acquired with
a 63 objective (Neofluar, NA 1.4; Carl Zeiss, Feldbach,
Switzerland) on an inverted microscope (Zeiss Axiovert
135), equipped with a digital charge-coupled device
(CCD) camera (Hamamatsu C4742-95-12ERG; Bucher
Biotec, Basel, Switzerland) and Openlab 3.1.2 software
(Improvision, Basel, Switzerland).
Alkaline phosphatase activity
Alkaline phosphatase (ALP) activity was determined
at the end of the exposure time, using p-nitrophenol
tablets as substrate (Sigma-Aldrich), and values were
quantified by comparison with a standard curve obtained
with serial dilutions of alkaline phosphatase from Esch-
erichia coli (Sigma-Aldrich). Enzymatic activity values
were then normalized to the total protein content deter-
mined by total cellular protein assay.
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Total cellular protein
Scaffolds colonized by cells were rinsed twice with
PBS, and total protein was determined in cell lysates by
protein assay (RC DC protein assay kit II; Bio-Rad, Her-
cules, CA). Total protein values were quantified by com-
parison with a standard curve obtained with serial dilu-
tions of bovine serum albumin contained in the Bio-Rad
protein assay kit II (Bio-Rad).
Osteocalcin synthesis
Quantitative determination of human -carboxylated
Gla-osteocalcin (Gla-OC) was achieved in culture su-
pernatants, using an in vitro immunoassay Gla-type os-
teocalcin EIA kit (Cambrex Bio Science, Walkersville,
Walkersville, MD). Measurements were done according
to the procedure furnished and sample concentrations
were determined by comparing their specific absorbance
with those obtained for the standards. Values represent
accumulation of the polypeptide during 72 h at the end
of the 4-week exposure to the scaffolds. They were then
normalized to the total protein content of the cell lysates
determined by total cellular protein assay.
In vitro mineralization
Porous constructs were rinsed twice with PBS. The de-
gree of in vitro calcium deposition was determined by von
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FIG. 1. Primary human fetal cells (top row) and adult osteoblasts (bottom row). Cells were seeded in the absence (left) or pres-
ence of composites PLA/HA IV (middle) and PLA/-TCP (right). Specific immunostaining for ALP (green), F-actin (red), and
DNA (blue) were used: primary antibody against alkaline phosphatase (R&D Systems, Minneapolis, MN) and as secondary an-
tibody Alexa 488-conjugated goat anti-mouse antibody (Molecular Probes, Eugene, OR); F-actin was probed with phalloidin–Alexa
568 (Molecular Probes) and DNA with DAPI (Fluka, Buchs, Switzerland). Images were acquired with a 63 objective (Neo-
fluar, NA 1.4; Carl Zeiss, Feldbach, Switzerland) on an inverted microscope (Zeiss Axiovert 135), equipped with a digital CCD
camera (Hamamatsu C4742-95-12ERG; Bucher Biotec, Basel, Switzerland) and Openlab 3.1.2 software (Improvision, Basel,
Switzerland). In all cases, adherent osteoblasts with normal morphologies and expressing alkaline phosphatase were observed,
indicating perfect biocompatibility of the tested scaffolds.
Kossa staining. This test is used extensively to reveal in
vitro mineralization. Briefly, the cells were fixed for 5 min
in 10% neutral formalin and washed three times with
deionized water. Samples were then stained with 5%
AgNO3 (in water). The plates were exposed for 1 h under
ultraviolet (UV) light and washed three times with water.
A solution of 5% sodium thiosulfate was then added for 2
min. Finally, scaffolds were washed three times with wa-
ter and examined for black clusters by light microscopy.
The experiment was performed twice, in triplicate.
Scanning electron microscopy
Cells were seeded as previously described and exposed
for 4 weeks to the osteogenic factors. Subsequently, cells
were fixed with glutaraldehyde, followed by a dehydra-
tion procedure in ethanol. The sample surfaces were
coated with gold for 2 min under 1 kV and observed with
a Philips XL30 scanning electron microscope. Using a
voltage of 5 kV and secondary electrons, surface topog-
raphy was examined. During SEM observations, energy-
dispersive X-ray microanalyses were carried out locally
at a high tension of 10 kV. Selective microanalysis en-
ables the detection of specific elements present on the
surface. For example, phosphorus and calcium, which are
present in calcium phosphate compounds produced dur-
ing mineralization by osteoblasts,29 can be analyzed.
X-ray photoelectron spectroscopy
X-ray photoelectron spectroscopy (XPS) was carried
out to confirm the presence of phosphorus. Moreover, it
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can indicate to which chemical group the element phos-
phorus belongs, and can also lead to a quantitative anal-
ysis. However, XPS is a technique sensitive to surface
roughness. Therefore bulk PLA platelets were prepared
by compression molding (195°C, 10 MPa, 10 min) and
then sterilized as previously described. Cells were seeded
and cultured under conditions similar to those used for
scaffolds. Subsequently, cells were fixed with glu-
taraldehyde, followed by a dehydration procedure in eth-
anol. XPS spectra were acquired on a Kratos AXIS Ul-
tra spectrophotometer operating at a base pressure of 10–9
mbar and equipped with a monochromatized Al K
source. Acquisition was done with a pass energy of 80
eV (acquisition time, 120 ms). Samples were investigated
with a charge compensation gun (emission current, 0.15
A). Chemical elements present on the surface can thus
be analyzed.
Statistical analysis
ALP and Gla-OC assays were carried out twice, each
time in triplicate. Similar results were obtained and data
are expressed as the mean of one experiment  SEM.
RESULTS
Cell proliferation and differentiation
When seeded directly on scaffolds, fetal and adult bone
cells did proliferate and differentiate in their immediate
vicinity (Fig. 1). Furthermore, both adult and fetal cells
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FIG. 2. SEM micrographs of uncolonized scaffolds (left) and of scaffolds colonized by fetal cells (middle) and adult cells
(right). After 4 weeks of treatment with osteogenic factors, cells were visible on the scaffold surfaces, with extracellular matrix
deposition and mineral crystals. The cells exhibited multiple cytoplasmic extensions that interconnected, wrapping the polymer
surface. Macropores were gradually obturated by a multilayered cover of cells. The width scale was chosen in order to focus on
cells lying on pore wall cross-sections and inside pores. Scale bars: 10 m.
were able to spread on scaffold surfaces, independently
of the foaming condition and of the presence or absence
of ceramic fillers (Fig. 2). Some cells covered the macro-
pore surfaces, whereas others sent cytoplasmic extensions
across the apertures. Thus, the macropores were gradu-
ally obturated by a multilayered coat of cells growing to-
ward the center of the pores. Cross-sections revealed that
fetal cells penetrated inside the scaffolds better than did
adult bone cells after 4 weeks of culture. Moreover, the
inner colonization was more pronounced with composite
scaffolds than with neat polymer foams. The results of
ALP and Gla-OC biochemical assays indicated that the
osteoblastic phenotype was either expressed by fetal cells
or maintained by adult osteoblasts in all scaffolds (Figs.
3 and 4). In the case of ALP activity of fetal cells, there
were two distinct groups of materials: PLA I and PLA II
induced a lower enzymatic activity level than did PLA/HA
IV and PLA/-TCP IV. With adult cells a low level of
ALP activity was measured for all materials tested. In the
case of osteocalcin synthesis, a similar low level was ob-
served with fetal cells in all scaffolds, whereas for adult
cells, neat PLAs led to less Gla-OC synthesis than did
composite scaffolds.
In vitro mineralization
The latest stage of osteoblast maturation is indicated
by extracellular matrix mineralization. Maturing cells
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may start to induce mineralization, that is, the precipita-
tion of small calcium phosphate crystals on the scaffold
surface. Small, rounded or more polygonally shaped crys-
tals were observed by scanning electron microscopy 
(Fig. 2). To determine their chemical nature, several ap-
proaches were taken.
von Kossa coloration of sample surfaces resulted in
dark coloration, which indicates the presence of calcium
(Fig. 5). All scaffolds in the presence of the two cell types
were stained. SEM topographic observations, associ-
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FIG. 3. Comparison of alkaline phosphatase enzymatic ac-
tivity from fetal (A) and adult (B) osteoblasts seeded on PLA
scaffolds after 4 weeks of exposition to osteogenic factors. The
ALP assay was carried out twice, each time in triplicate, and
results are expressed as the mean of one experiment  SEM.
Representative data of one experiment are shown.
FIG. 4. Comparison of -carboxylated Gla-osteocalcin syn-
thesized by fetal (A) and adult (B) osteoblasts seeded on PLA
scaffolds after 4 weeks of exposure to osteogenic factors. The
Gla-OC assay was carried out twice, each time in triplicate, and
results are expressed as the mean of one experiment  SEM.
Representative data of one experiment are shown.
FIG. 5. von Kossa staining of PLA scaffolds. Fetal or adult
bone cells were seeded on PLA samples as described in Mate-
rials and Methods. After 4 weeks of treatment with osteogenic
factors, cells were fixed and samples were stained to reveal in
vitro mineralization.
ated with X-ray microanalysis, were conducted on gold-
coated samples with a high tension of 10 kV (Fig. 6A).
On PLA scaffolds, crystals containing calcium (peaks at
3.71 and 4.02 keV) and probably phosphorus (peaks at
2.02 and 2.12 keV) were detected. However, phosphorus
peaks were in the same area as those of gold, from coat-
ing (peak at 2.30 keV). To confirm the presence of phos-
phorus on the scaffold surface after cell proliferation and
differentiation, X-ray photoelectron spectroscopy (XPS)
was carried out on flat PLA samples after 4 weeks of cell
culture (Fig. 6B). Composite samples were not tested, be-
cause they already contained calcium and phosphorus,
which would have been detected, along with potential el-
ements created by mineralization, by XPS. Phosphorus
and calcium peaks are clearly visible, therefore confirm-
ing the presence of calcium phosphates on the PLA sur-
face after fetal cell proliferation and differentiation. Oxy-
gen, carbon, and nitrogen peaks result from the presence
of extracellular matrix proteins on the surface.
DISCUSSION
The use of the extrusion method, to mix ceramic and
polymer, followed by gas foaming, leads to scaffolds with
controlled porosity and morphology, and targeted me-
chanical properties25 without the use of potentially toxic
organic solvents.30,31 Fillers are mixed with the polymer
at a given content, and homogeneously distributed in the
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composite preform before foaming. They are also well
dispersed in pore walls in the final composite scaffolds,
as evidenced by two-dimensional micro-computed to-
mography analysis (data not shown). Importantly, the
filler content is not modified by the gas-foaming process.
Compared with scaffolds described in the literature,
highly porous scaffolds were prepared, with improved re-
sistance in compression (Table 3). Scaffolds developed
in this study showed high osteoconductive potential, al-
lowing proliferation of bone cells through the porous
structures. Fetal bone cells were already characterized for
their high osteogenic potential,27 and their proliferative
aptitude observed on artificial structures is of major in-
terest from the perspective of the use of human primary
fetal bone cells in tissue engineering. During the expo-
sure, fetal and adult bone cells seeded on the scaffolds
were pushed toward differentiation, and osteoblastic
genes such as cbfa-1, 1 chain of type I collagen, alka-
line phosphatase, and osteocalcin were expressed (data
not shown). The cells seeded on these engineered scaf-
folds held their ability to differentiate into mature os-
teoblasts. On all scaffolds investigated, ALP and Gla-OC
markers were expressed by fetal and adult cells. How-
ever, these two parameters follow different kinetics: al-
kaline phosphatase is expressed at an early stage of cell
development,32–36 whereas in vitro studies showed that
osteocalcin is a marker of late osteoblast differentia-
tion.37–39 Therefore, the higher level of ALP enzymatic
activity observed in this article with fetal cells compared
with adult bone cells is not surprising. Likewise, the level
of Gla-OC synthesis was higher in adult bone cells com-
pared with fetal bone cells. As mature osteoblasts, adult
bone cells are already involved in extracellular matrix de-
position. Synthesis of osteocalcin confirmed their fully
differentiated osteoblastic phenotype. With adult or fetal
cells, no significant differences between the three poly-
mers PLA I, PLA II, and PLA III were observed. There-
fore cell development did not seem to be affected by a
difference in porosity or pore size.
As far as composite scaffolds PLA/HA IV and PLA/-
TCP IV are concerned, a higher level of ALP activity
was observed for fetal cells, and a higher level of Gla-
OC synthesis was measured for adult cells. The presence
of ceramic fillers, either HA or -TCP, therefore favored
differentiation of fetal and adult bone cells owing to their
osteoconductive properties.16,26,40 Finally, extracellular
matrix deposition and in vitro mineralization were ob-
served on all scaffolds, indicating that complete differ-
entiation did occur. Fetal bone cells colonized the whole
of PLA and composite scaffolds, whereas adult bone cells
showed mainly superficial growth. von Kossa staining
corroborated these observations. Composites seeded with
fetal cells displayed more extensive proliferation than did
neat PLA. X-ray microanalyses and XPS detected cal-
cium and phosphorus on cell-cultured surfaces but not on
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FIG. 6. Identification of mineral crystal deposits observed on
a PLA I sample colonized by fetal bone cells: (A) energy-dis-
persive X-ray microanalysis and (B) X-ray photoelectron spec-
troscopy. Similar results were obtained with adult cells, and
with PLA/HA IV and PLA/-TCP IV surfaces. Samples ana-
lyzed refer to sample B of Fig. 2.
control specimens, indicating that crystals were produced
only in the presence of cells proliferating and differenti-
ating on the scaffolds, and were not the result of simple
chemical precipitation. After 8 weeks of culture with fe-
tal cells, no sign of polymer degradation was noticed, ei-
ther structurally or by acidification of the culture medium.
Moreover, no alteration of mechanical properties was ob-
served (data not shown). This is particularly worthwhile
for orthopedic implants, which must support significant
loading.
We conclude that porous structures obtained by super-
critical gas foaming of PLA offer suitable conditions for
osteoblasts to achieve full differentiation. This solvent-
free method may be of great interest for bone tissue en-
gineering, to obtain open frames with controlled parame-
ters, such as porosity, pore size, and connectivity. This
procedure enables mass production of biocompatible sam-
ples with improved mechanical properties, as expected,
and as has also been obtained by other methods.15,41 Fur-
thermore, we demonstrate for the first time that once
seeded with human fetal bone cells, such osteoconductive
scaffolds are promising because of the high osteogenic
potential of these cells. Fetal-associated tissues such as
placenta, amniotic liquid, and umbilical cord are poten-
tial sources of cells for tissue engineering.42–45 Human fe-
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tal liver cells have been used for transplantation when
there was no perfectly matched donor for marrow trans-
plantation.46 Neuronal conditions such as Huntington’s47
or Parkinson’s disease48 have been treated with fetal neu-
roblasts. Concerning bone grafts, the decreasing ability of
adult mesenchymal stem cells derived from osteoporotic
donors to differentiate into the osteogenic lineage was
demonstrated.49 Thus, a bank of fetal bone cells could be
of great interest for tissue-engineering applications.
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TABLE 3. COMPARISON BETWEEN FOAM PROPERTIES OBTAINED IN THIS STUDY AND IN THE LITERATUREa
Elastic
collapse Average Structure/
Porosity Modulus stress diameter foaming
Study Material (%) (MPa) (MPa) (m) Anisotropy technique
Targeted Cancellous bone 75b 100–300c 5–10c 200–400d Yes Anisotropy,
properties interconnected
This study Neat PLA 70–90 20–180c 2–3.5c 200–100d Yes Pore size
gradient
This study PLA–ceramic 75–90 30–200c 2–6c 200–100d Yes Pore size
gradient
Marra et PLGA — 2.5  0.7c —c —d No Solvent
al. (Ref. 15) PLGA–10% HA — 12.5  3.2c —c —d No casting
Ma et al. L-PLA 92.7 6.42  1.44c 0.32  0.04c 10–100d Yes Microtubular/TIPS
(Ref. 40) PLA–50% HA 89.2 10.87  3.2c0 0.39  0.01c 10–100d Yes Microtubular/TIPS
Walsh et al. HA — —c 9c —d No HA coated with PCL
(Ref. 50) HA–PCL — —c 37c —d No HA coated with PCL
Boccaccini PLGA 94.3 8c —c —d Yes TIPS
and Maquet PLGA–50% 89.9 23c —c —d Yes TIPS
(Ref. 41) Bioglass
Wei and Ma L-PLA 93.0 4.3c —c —d Yes Nano-HA/TIPS
(Ref. 51) PLA  50% HA 91.8 8.3c —c —d
Abbreviations: HA, hydroxyapatite; PCL, polycaprolactone; PLA/L-PLA, poly(L-lactic acid); PLGA, poly(lactic-co-glycolic
acid); TIPS, thermally induced phase separation.
aFrom Refs. 15, 40, 41, 50, and 51.
bSee Ref. 52.
cSee Ref. 53 and 54.
dSee Ref. 55.
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